1. Home
  2. DARE vs VCIG Comparison

DARE vs VCIG Comparison

Compare DARE & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DARE
  • VCIG
  • Stock Information
  • Founded
  • DARE 2015
  • VCIG 2013
  • Country
  • DARE United States
  • VCIG Malaysia
  • Employees
  • DARE N/A
  • VCIG N/A
  • Industry
  • DARE Biotechnology: Pharmaceutical Preparations
  • VCIG Diversified Commercial Services
  • Sector
  • DARE Health Care
  • VCIG Consumer Discretionary
  • Exchange
  • DARE Nasdaq
  • VCIG Nasdaq
  • Market Cap
  • DARE 28.0M
  • VCIG 22.5M
  • IPO Year
  • DARE N/A
  • VCIG 2023
  • Fundamental
  • Price
  • DARE $2.25
  • VCIG $6.32
  • Analyst Decision
  • DARE Strong Buy
  • VCIG
  • Analyst Count
  • DARE 2
  • VCIG 0
  • Target Price
  • DARE $10.00
  • VCIG N/A
  • AVG Volume (30 Days)
  • DARE 123.3K
  • VCIG 325.9K
  • Earning Date
  • DARE 11-13-2025
  • VCIG 10-06-2025
  • Dividend Yield
  • DARE N/A
  • VCIG N/A
  • EPS Growth
  • DARE N/A
  • VCIG N/A
  • EPS
  • DARE N/A
  • VCIG 162.63
  • Revenue
  • DARE N/A
  • VCIG $32,903,041.00
  • Revenue This Year
  • DARE $6,864.02
  • VCIG N/A
  • Revenue Next Year
  • DARE $4,922.46
  • VCIG N/A
  • P/E Ratio
  • DARE N/A
  • VCIG $0.04
  • Revenue Growth
  • DARE N/A
  • VCIG 24.77
  • 52 Week Low
  • DARE $1.83
  • VCIG $6.01
  • 52 Week High
  • DARE $9.19
  • VCIG $4,644.00
  • Technical
  • Relative Strength Index (RSI)
  • DARE 61.86
  • VCIG 54.10
  • Support Level
  • DARE $2.11
  • VCIG $6.01
  • Resistance Level
  • DARE $2.28
  • VCIG $7.22
  • Average True Range (ATR)
  • DARE 0.07
  • VCIG 0.83
  • MACD
  • DARE 0.02
  • VCIG -0.42
  • Stochastic Oscillator
  • DARE 91.96
  • VCIG 6.26

About DARE Dare Bioscience Inc.

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

Share on Social Networks: